Fenofibrate and the kidney: an overview

摘要: Background Fenofibrate has been used for the management of atherogenic dyslipidaemia many years. Reports fenofibrate-associated increases in serum creatinine (SCr) levels raised concerns regarding deleterious effects on renal function. Design In this narrative review, we discuss available literature effect fenofibrate kidney. Results Most clinical studies showed a rapid (within weeks) raising SCr levels. This was often accompanied by declined estimated glomerular filtration rate. Risk predictors adverse might include increased age, impaired function and high-dose treatment. Also, concomitant use medications affecting hemodynamics (e.g. angiotensin-converting enzyme-inhibitors (ACEi) angiotensin receptor blockers) may predispose to Interestingly, were transient reversible even without treatment discontinuation. Furthermore, associated with slower progression impairment albuminuria long-term basis. be protective against pathological changes diabetic nephropathy hypertensive glomerulosclerosis. In context, it is uncertain whether increase mirrors true deterioration. Several theories have expressed. The most dominant one involved inhibition vasodilatory prostaglandins reducing plasma flow pressure. Increased secretion or reduced clearance also suggested. These hypotheses should settled further studies. Conclusions Fenofibrate not nephrotoxic drug. However, close monitoring relevant especially high-risk patients. Increases ≥30% can impose